BIIB250509P160000
- 0.00
- 0.000.00%
Biogen Newsroom
Biogen (NasdaqGS:BIIB) Selects Multiple Co-Lead Underwriters for US$1 Billion Fixed-Income Offering
Biogen Is Maintained at Outperform by Mizuho
Biogen Price Target Cut to $169.00/Share From $207.00 by Mizuho
Biogen Analyst Ratings
Mizuho Securities Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $169
Mizuho Securities Remains a Buy on Biogen (BIIB)
Mizuho Cuts Price Target on Biogen to $169 From $207
Express News | Biogen Files for Two-Part Senior Notes Offering; Size Not Disclosed - SEC Filing
Biogen Director Makes Strategic Stock Purchase
J.P. Morgan Maintains Biogen(BIIB.US) With Hold Rating, Cuts Target Price to $175
JP Morgan Maintains Neutral on Biogen, Lowers Price Target to $175
New Analyst Forecast: $BIIB Given $187.0 Price Target
BTIG Maintains Biogen(BIIB.US) With Hold Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: OKYO Pharma Limited Sponsored ADR (OKYO), Biogen (BIIB) and Cigna (CI)
Piper Sandler Keeps Their Hold Rating on Biogen (BIIB)
A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $121 to $255
Biogen First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Biogen Emerging as 'Leaner, Less Risky' Company, RBC Says
Biogen Is Maintained at Buy by Canaccord Genuity
Biogen Price Target Cut to $220.00/Share From $265.00 by Canaccord Genuity